TAPUR: 진행성 암 환자의 종양 유전자의 특정 이상을 표적으로 하는 식품의약국(FDA) 승인 약물의 사용 테스트 (TAPUR)
Targeted Agent and Profiling Utilization Registry(TAPUR) 연구
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
********************************************************************
Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.
********************************************************************
연구 개요
상태
개입 / 치료
- 의약품: Sunitinib (CLOSED TO ENROLLMENT)
- 의약품: Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)
- 의약품: Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- 의약품: Olaparib (CLOSED TO ENROLLMENT)
- 의약품: Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)
- 의약품: Abemaciclib (CLOSED TO ENROLLMENT)
- 의약품: Talazoparib (CLOSED TO ENROLLMENT)
- 의약품: Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT)
- 의약품: Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)
- 의약품: Futibatinib
- 의약품: Dabrafenib plus Trametinib
- 의약품: Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
상세 설명
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Laurie Smith, MA
- 전화번호: www.tapur.org
- 이메일: tapur@asco.org
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35294
- 모병
- University of Alabama at Birmingham Comprehensive Cancer Center
-
수석 연구원:
- Mehmet Akce, MD
-
연락하다:
- Kun Yuan
- 전화번호: 205-644-2584
- 이메일: kunyuan@uabmc.edu
-
-
Arizona
-
Phoenix, Arizona, 미국, 85338
- 모병
- Cancer Treatment Centers of America-Phoenix
-
수석 연구원:
- Sagun Shrestha, MD
-
연락하다:
- Alex Lizzul
- 전화번호: 602-872-5654
- 이메일: alizzul@coh.org
-
-
California
-
Auburn, California, 미국, 95602
- 모병
- Sutter Auburn
-
연락하다:
- Kirsten Babski
- 전화번호: 916-878-4990
- 이메일: BabskiK@sutterhealth.org
-
수석 연구원:
- Nitin Rohatgi, MD
-
Berkeley, California, 미국, 94705
- 모병
- Sutter Alta Bates
-
연락하다:
- Christopher Tang
- 전화번호: 510-204-3428
- 이메일: Christopher.Tang@sutterhealth.org
-
수석 연구원:
- Nitin Rohatgi, MD
-
Los Angeles, California, 미국, 90025
- 모병
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
-
연락하다:
- Teri Mata
- 전화번호: 310-231-2115
- 이메일: tmata@theangelesclinic.org
-
수석 연구원:
- Omid Hamid, MD
-
Oakland, California, 미국, 94611
- 모병
- Kaiser Permanente - Oakland Medical Center
-
연락하다:
- Desiree Goldstein
- 이메일: desiree.goldstein@kp.org
-
수석 연구원:
- Jennifer M Suga, MD
-
Palo Alto, California, 미국, 94301
- 모병
- Sutter Palo Alto Medical Foundation: Palo Alto
-
연락하다:
-
Roseville, California, 미국, 95661
- 모병
- Kaiser Permanente - Roseville Medical Center
-
연락하다:
- Desiree Goldstein
- 이메일: desiree.goldstein@kp.org
-
수석 연구원:
- Jennifer M Suga, MD
-
Roseville, California, 미국, 95661
- 모병
- Sutter Roseville
-
연락하다:
- Kirsten Babski
- 전화번호: 916-878-4990
- 이메일: BabskiK@sutterhealth.org
-
수석 연구원:
- Nitin Rohatgi, MD
-
Sacramento, California, 미국, 95814
- 모병
- Kaiser Permanente - Sacramento Medical Center
-
연락하다:
- Desiree Goldstein
- 이메일: desiree.goldstein@kp.org
-
수석 연구원:
- Jennifer M Suga, MD
-
Sacramento, California, 미국, 95816
- 모병
- Sutter Sacramento
-
연락하다:
-
수석 연구원:
- Nitin Rohatgi, MD
-
San Francisco, California, 미국, 94115
- 모병
- California Pacific Medical Center Research Institute
-
연락하다:
- 전화번호: 415-600-1654
- 이메일: clinicalresearch@sutterhealth.org
-
수석 연구원:
- Nitin Rohatgi, MD
-
San Francisco, California, 미국, 94080
- 모병
- Kaiser Permanente - South San Francisco Medical Center
-
연락하다:
- Desiree Goldstein
- 이메일: desiree.goldstein@kp.org
-
수석 연구원:
- Jennifer M Suga, MD
-
San Francisco, California, 미국, 94115
- 모병
- Kaiser Permanente - San Francisco Medical Center
-
연락하다:
- Desiree Goldstein
- 이메일: desiree.goldstein@kp.org
-
수석 연구원:
- Jennifer M Suga, MD
-
San Francisco, California, 미국, 94115
- 모병
- Sutter Cancer Research Consortium
-
연락하다:
- Laurel Brechtel
- 전화번호: 415-600-1654
- 이메일: BrechtLa@cpmcri.org
-
수석 연구원:
- Stacy D'Andre, MD
-
San Jose, California, 미국, 95119
- 모병
- Kaiser Permanente - San Jose Medical Center
-
연락하다:
- Desiree Goldstein
- 이메일: desiree.goldstein@kp.org
-
수석 연구원:
- Jennifer M Suga, MD
-
San Leandro, California, 미국, 94577
- 모병
- Kaiser Permanente - San Leandro Medical Center
-
연락하다:
- Desiree Goldstein
- 이메일: desiree.goldstein@kp.org
-
수석 연구원:
- Jennifer M Suga, MD
-
Santa Barbara, California, 미국, 93105
- 모병
- Sutter Sansum Clinic
-
수석 연구원:
- Nitin Rohatgi, MD
-
연락하다:
- Selina Perez
- 전화번호: 831-458-5837
- 이메일: Selina.Perez@sutterhealth.org
-
Santa Clara, California, 미국, 95051
- 모병
- Kaiser Permanente - Santa Clara Medical Center
-
연락하다:
- Desiree Goldstein
- 이메일: desiree.goldstein@kp.org
-
수석 연구원:
- Jennifer M Suga, MD
-
Santa Cruz, California, 미국, 95065
- 모병
- Sutter Palo Alto Medical Foundation: Santa Cruz
-
연락하다:
-
Santa Cruz, California, 미국, 994538
- 모병
- Sutter Palo Alto Medical Foundation: Fremont
-
연락하다:
-
Sunnyvale, California, 미국, 94086
- 모병
- Sutter Palo Alto Medical Foundation: Sunnyvale
-
연락하다:
-
Vallejo, California, 미국, 94589
- 모병
- Kaiser Permanente - Vallejo Medical Center
-
연락하다:
- Desiree Goldstein
- 이메일: desiree.goldstein@kp.org
-
수석 연구원:
- Jennifer M. Suga, MD
-
Walnut Creek, California, 미국, 94596
- 모병
- Kaiser Permanente - Walnut Creek Medical Center
-
연락하다:
- Desiree Goldstein
- 이메일: desiree.goldstein@kp.org
-
수석 연구원:
- Jennifer M Suga, MD
-
-
Connecticut
-
Bridgeport, Connecticut, 미국, 06606
- 모병
- Saint Vincent's Medical Center (SVMC)
-
연락하다:
- 전화번호: 860-972-4700
- 이메일: CancerResearchSupport@hhchealth.org
-
수석 연구원:
- Wylie Hosmer, MD
-
Hartford, Connecticut, 미국, 06102
- 모병
- Hartford Hospital
-
연락하다:
- 전화번호: 860-972-4700
- 이메일: CancerResearchSupport@hhchealth.org
-
수석 연구원:
- Wylie Hosmer, MD
-
Meriden, Connecticut, 미국, 06451
- 모병
- Midstate Medical Center (MSMC)
-
연락하다:
- 전화번호: 860-972-4700
- 이메일: CancerResearchSupport@hhchealth.org
-
수석 연구원:
- Wylie Hosmer, MD
-
New Britain, Connecticut, 미국, 06053
- 모병
- The Hospital of Central Connecticut (HOCC) Cancer Center
-
수석 연구원:
- Wylie Hosmer, MD
-
연락하다:
- 전화번호: 8609724700
- 이메일: CancerResearchSupport@hhchealth.org
-
Norwich, Connecticut, 미국, 06360
- 모병
- William W. Backus Hospital
-
연락하다:
- 전화번호: 860-972-4700
- 이메일: CancerResearchSupport@hhchealth.org
-
수석 연구원:
- Wylie Hosmer, MD
-
Torrington, Connecticut, 미국, 06790
- 모병
- Charlotte Hungerford
-
연락하다:
- 전화번호: 860-972-4700
- 이메일: CancerResearchSupport@hhchealth.org
-
수석 연구원:
- Wylie Hosmer, MD
-
Willimantic, Connecticut, 미국, 06226
- 모병
- Windham Hospital (WH)
-
연락하다:
- 전화번호: 860-972-4700
- 이메일: CancerResearchSupport@hhchealth.org
-
수석 연구원:
- Wylie Hosmer, MD
-
-
Florida
-
Altamonte Springs, Florida, 미국, 32701
- 모집하지 않고 적극적으로
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Aventura, Florida, 미국, 33180
- 모병
- University of Miami/Sylvester Cancer Institute - Aventura
-
연락하다:
- Carolina Troche, BS
- 전화번호: 305-243-1481
- 이메일: cxt582@med.miami.edu
-
수석 연구원:
- Carmen Calfa, MD
-
Bonita Springs, Florida, 미국, 34135
- 모집하지 않고 적극적으로
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Bradenton, Florida, 미국, 34211
- 모집하지 않고 적극적으로
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Brandon, Florida, 미국, 33511
- 모집하지 않고 적극적으로
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Cape Coral, Florida, 미국, 33909
- 모집하지 않고 적극적으로
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Clearwater, Florida, 미국, 33761
- 모집하지 않고 적극적으로
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Coral Gables, Florida, 미국, 33146
- 모병
- University of Miami/Sylvester Cancer Institute - Lennar
-
연락하다:
- Carolina Troche, BS
- 전화번호: 305-243-1481
- 이메일: cxt582@med.miami.edu
-
수석 연구원:
- Carmen Calfa, MD
-
Deerfield Beach, Florida, 미국, 33442
- 모병
- University of Miami/Sylvester Cancer Institute - Deerfield Beach
-
연락하다:
- Carolina Troche, BS
- 전화번호: 305-243-1481
- 이메일: cxt582@med.miami.edu
-
수석 연구원:
- Carmen Calfa, MD
-
Fort Lauderdale, Florida, 미국, 33308
- 모병
- Holy Cross Hospital
-
수석 연구원:
- Zdenka Segota, MD
-
연락하다:
- 전화번호: 7347123671
- 이메일: MCRCwebsitecontactform@trinity-health.org
-
Fort Myers, Florida, 미국, 33901
- 모집하지 않고 적극적으로
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Fort Myers, Florida, 미국, 33905
- 모집하지 않고 적극적으로
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Fort Myers, Florida, 미국, 33908
- 모집하지 않고 적극적으로
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Gainesville, Florida, 미국, 32610
- 모병
- University of Florida Health
-
수석 연구원:
- Thomas George, MD
-
연락하다:
- Anna Kukulka, RN, BSN
- 전화번호: 352-293-2551
- 이메일: akukulka@ufl.edu
-
Gainesville, Florida, 미국, 32605
- 모집하지 않고 적극적으로
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Largo, Florida, 미국, 33770
- 모집하지 않고 적극적으로
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Lecanto, Florida, 미국, 34461
- 모집하지 않고 적극적으로
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Miami, Florida, 미국, 33136
- 모병
- University of Miami Sylvester Comprehensive Cancer Center
-
연락하다:
- Carolina Troche, BS
- 전화번호: 305-243-1481
- 이메일: cxt582@med.miami.edu
-
수석 연구원:
- Carmen Calfa, MD
-
Miami, Florida, 미국, 33136
- 모병
- University of Miami/Sylvester Cancer Institute - Alex's Place
-
연락하다:
- Carolina Troche, BS
- 전화번호: 305-243-1481
- 이메일: cxt582@med.miami.edu
-
수석 연구원:
- Carmen Calfa, MD
-
Miami, Florida, 미국, 33136
- 모병
- University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building
-
연락하다:
- Carolina Troche, BS
- 전화번호: 305-243-1481
- 이메일: cxt582@med.miami.edu
-
수석 연구원:
- Carmen Calfa, MD
-
Miami, Florida, 미국, 33176
- 모병
- University of Miami/Sylvester Cancer Institute - Kendall
-
연락하다:
- Carolina Troche, BS
- 전화번호: 305-243-1481
- 이메일: cxt582@med.miami.edu
-
수석 연구원:
- Carmen Calfa, MD
-
Miami, Florida, 미국, 33181
- 모병
- University of Miami/Sylvester Cancer Institute - Sole Mia
-
연락하다:
- Carolina Troche, BS
- 전화번호: 305-243-1481
- 이메일: cxt582@med.miami.edu
-
수석 연구원:
- Carmen Calfa, MD
-
Naples, Florida, 미국, 34102
- 모집하지 않고 적극적으로
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Ocala, Florida, 미국, 34474
- 모집하지 않고 적극적으로
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Orange City, Florida, 미국, 32763
- 모집하지 않고 적극적으로
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Orlando, Florida, 미국, 32806
- 모집하지 않고 적극적으로
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Plantation, Florida, 미국, 33324
- 모병
- University of Miami/Sylvester Cancer Institute - Plantation
-
연락하다:
- Carolina Troche, BS
- 전화번호: 305-243-1481
- 이메일: cxt582@med.miami.edu
-
수석 연구원:
- Carmen Calfa, MD
-
Port Charlotte, Florida, 미국, 33980
- 모집하지 않고 적극적으로
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Sarasota, Florida, 미국, 34236
- 모집하지 않고 적극적으로
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Sarasota, Florida, 미국, 34239
- 모집하지 않고 적극적으로
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
St. Petersburg, Florida, 미국, 33701
- 모집하지 않고 적극적으로
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Tampa, Florida, 미국, 33607
- 모집하지 않고 적극적으로
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Tavares, Florida, 미국, 32778
- 모집하지 않고 적극적으로
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
The Villages, Florida, 미국, 32159
- 모집하지 않고 적극적으로
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Trinity, Florida, 미국, 34655
- 모집하지 않고 적극적으로
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Venice, Florida, 미국, 34285
- 모집하지 않고 적극적으로
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Venice, Florida, 미국, 34292
- 모집하지 않고 적극적으로
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Winter Park, Florida, 미국, 32789
- 모집하지 않고 적극적으로
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- 모병
- Emory University Winship Cancer Institute
-
수석 연구원:
- Olatunji Alese, MD
-
연락하다:
- Krystal Bagley
- 전화번호: 404-778-8670
- 이메일: krystal.joi.bagley@emory.edu
-
Atlanta, Georgia, 미국, 30265
- 모병
- Cancer Treatment Centers of America - Atlanta
-
수석 연구원:
- Bamidele Adesunloye, MD
-
연락하다:
- Elizabeth McKoy, RN, BSN
- 전화번호: 770-400-7177
- 이메일: emckoy@coh.org
-
Savannah, Georgia, 미국, 31405
- 모병
- Summit Cancer Care
-
수석 연구원:
- Mark Taylor, MD
-
연락하다:
- Stephanie Smith, RN, MSN, OCN
- 전화번호: 9128195723
- 이메일: smiths1@sjchs.org
-
Savannah, Georgia, 미국, 31405
- 모병
- Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion
-
수석 연구원:
- Mark Taylor, MD
-
연락하다:
- Stephanie Smith, RN, MSN, OCN
- 전화번호: 9128195723
- 이메일: smiths1@sjchs.org
-
Savannah, Georgia, 미국, 31405
- 모병
- Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute
-
수석 연구원:
- Mark Taylor, MD
-
연락하다:
- Stephanie Smith, RN, MSN, OCN
- 전화번호: 19128195723
- 이메일: smiths1@sjchs.org
-
Savannah, Georgia, 미국, 31405
- 모병
- Lewis Cancer & Research Pavilion
-
연락하다:
- Stephanie Smith, RN, MSN, OCN
- 전화번호: 912-819-5723
- 이메일: smiths1@sjchs.org
-
수석 연구원:
- Mark Taylor, MD
-
-
Hawaii
-
Honolulu, Hawaii, 미국, 96813
- 모병
- The Queen's Medical Center - POB I
-
수석 연구원:
- Jared Acoba, MD
-
연락하다:
- Tim Kelleher
- 전화번호: 8086918582
- 이메일: tkelleher@queens.org
-
Honolulu, Hawaii, 미국, 96813
- 모병
- The Queen's Medical Center - Punchbowl
-
수석 연구원:
- Jared Acoba, MD
-
연락하다:
- Tim Kelleher
- 전화번호: 808 691-8582
- 이메일: tkelleher@queens.org
-
Honolulu, Hawaii, 미국, 96817
- 모병
- The Queen's Medical Center - Kuakini
-
수석 연구원:
- Jared Acoba, MD
-
연락하다:
- Tim Kelleher
- 전화번호: 8086918582
- 이메일: tkelleher@queens.org
-
‘Ewa Beach, Hawaii, 미국, 96706
- 모병
- The Queen's Medical Center - West Oahu
-
수석 연구원:
- Jared Acoba, MD
-
연락하다:
- Tim Kelleher
- 전화번호: 8086918582
- 이메일: tkelleher@queens.org
-
-
Illinois
-
Chicago, Illinois, 미국, 60099
- 모병
- Cancer Treatment Centers of America-Chicago
-
수석 연구원:
- Evan Pisick, MD
-
연락하다:
- Office of Clinical Trials
- 전화번호: 847-731-1777
- 이메일: CHIResearch@coh.org
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46250
- 모병
- Community Health Network (The University of Texas MD Anderson Cancer Center)
-
수석 연구원:
- Funda Meric-Bernstam, MD
-
연락하다:
- Kshipra Sharma, MPH, MS
- 전화번호: 713-745-8431
- 이메일: Ksharma2@MDAnderson.org
-
-
Maine
-
Augusta, Maine, 미국, 04330
- 모병
- Harold Alfond Center for Cancer Care
-
연락하다:
- Sandra Neptune, BSN, RN
- 전화번호: 207-626-4811
- 이메일: sandra.neptune@mainegeneral.org
-
수석 연구원:
- Lindsay Hathaway, MD
-
Augusta, Maine, 미국, 04330
- 모병
- Jackson Laboratory - Maine Cancer Genomics Initiative
-
연락하다:
- Petra Helbig, CCRP
- 전화번호: 207-664-4659
- 이메일: Petra.Helbig@jax.org
-
수석 연구원:
- Jens Rueter, MD
-
Belfast, Maine, 미국, 04915
- 모병
- Waldo County General Hospital
-
수석 연구원:
- Roger Inhorn, MD
-
연락하다:
- Jen - Dalton, MHA, BSN, RN
- 전화번호: 2072948291
- 이메일: JDalton@mmc.org
-
Biddeford, Maine, 미국, 04005
- 모병
- SMHC Cancer Care and Blood Disorders -Biddeford
-
수석 연구원:
- Roger Inhorn, MD
-
연락하다:
- Jen - Dalton
- 전화번호: 2072948291
- 이메일: JDalton@mmc.org
-
Brewer, Maine, 미국, 04412
- 모병
- Northern Light Cancer Care
-
수석 연구원:
- Sarah Sinclair, MD
-
연락하다:
- Carla Mancini, MHA, BSN, RN
- 전화번호: 207-973-5581
- 이메일: cmancini@northernlight.org
-
Brewer, Maine, 미국, 04412
- 모병
- Raish Peavey Haskell Children's Cancer and Treatment Center
-
수석 연구원:
- Sarah Sinclair, MD
-
연락하다:
- Carla C Mancini, RN, BSN, OCN
- 전화번호: 2079735581
- 이메일: cmancini@northernlight.org
-
Brunswick, Maine, 미국, 04011
- 모병
- MaineHealth Cancer Care -Brunswick
-
수석 연구원:
- Roger Inhorn, MD
-
연락하다:
- Jen - Dalton, MHA, BSN, RN
- 전화번호: 2072948291
- 이메일: JDalton@mmc.org
-
Kennebunk, Maine, 미국, 04043
- 모병
- New England Cancer Specialist
-
수석 연구원:
- Christian Thomas, MD
-
연락하다:
- Patricia C Collins
- 전화번호: 2073033422
- 이메일: collip@newecs.org
-
Kittery, Maine, 미국, 03904
- 모병
- York Hopsital Oncology & Infusion Care in Kittery
-
수석 연구원:
- Marilyn McLaughlin, MD
-
연락하다:
- Brenda i Kiberd, RN
- 전화번호: 2073616115
- 이메일: Brenda.Kiberd@yorkhospital.com
-
Norway, Maine, 미국, 04268
- 모병
- Stephens Memorial Hospital
-
수석 연구원:
- Roger Inhorn, MD
-
연락하다:
- Jen - Dalton, MHA, BSN, RN
- 전화번호: 2072948291
- 이메일: JDalton@mmc.org
-
Rockport, Maine, 미국, 04856
- 모병
- Penobscot Bay Medical Center
-
수석 연구원:
- Roger Inhorn, MD
-
연락하다:
- Jen - Dalton, MHA, BSN, RN
- 전화번호: 2072948291
- 이메일: JDalton@mmc.org
-
Sanford, Maine, 미국, 04073
- 모병
- SMHC Cancer Care and Blood Disorders -Sandford
-
수석 연구원:
- Roger Inhorn, MD
-
연락하다:
- Jen - Dalton, MHA, BSN, RN
- 전화번호: 2072948291
- 이메일: JDalton@mmc.org
-
Scarborough, Maine, 미국, 04074
- 모병
- Maine Children's Cancer Program
-
수석 연구원:
- Roger Inhorn, MD
-
연락하다:
- Jen - Dalton, MHA, BSN, RN
- 전화번호: 2072948291
- 이메일: JDalton@mmc.org
-
Scarborough, Maine, 미국, 04074
- 모병
- Maine Medical Partner's Women's Health
-
수석 연구원:
- Roger Inhorn, MD
-
연락하다:
- Jen - Dalton, MHA, BSN, RN
- 전화번호: 2072948291
- 이메일: JDalton@mmc.org
-
Scarborough, Maine, 미국, 04074
- 모병
- New England Cancer Specialist
-
수석 연구원:
- Christian Thomas, MD
-
연락하다:
- Patricia Collins, BA, CCRC
- 전화번호: 207-303-3422
- 이메일: collip@newecs.org
-
South Portland, Maine, 미국, 04106
- 모병
- MaineHealth Cancer Care -South Portland
-
연락하다:
- Jen Dalton, MHA, BSN, RN
- 전화번호: 207-294-8291
- 이메일: JDalton@mmc.org
-
수석 연구원:
- Roger Inhorn, MD
-
Topsham, Maine, 미국, 04086
- 모병
- New England Cancer Specialist
-
수석 연구원:
- Christian Thomas, MD
-
연락하다:
- Patricia C Collins, BA, CCRC
- 전화번호: 12073033422
- 이메일: collip@newecs.org
-
Wells, Maine, 미국, 04090
- 모병
- York Hospital Oncology & Infusion Care in Wells
-
수석 연구원:
- Marilyn McLaughlin, MD
-
연락하다:
- Brenda Kiberd, RN
- 전화번호: 207-361-6115
- 이메일: Brenda.Kiberd@yorkhospital.com
-
York Village, Maine, 미국, 03909
- 모병
- York Hospital Oncology & Infusion Care in York
-
수석 연구원:
- Marilyn McLaughlin, MD
-
연락하다:
- Brenda i Kiberd, RN
- 전화번호: 2073616115
- 이메일: Brenda.Kiberd@yorkhospital.com
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모집하지 않고 적극적으로
- University of Michigan
-
Ann Arbor, Michigan, 미국, 48106
- 모병
- Trinity Health Ann Arbor Hospital
-
수석 연구원:
- Elie Dib, MD
-
연락하다:
- 전화번호: 7347123671
- 이메일: MCRCwebsitecontactform@trinity-health.org
-
Detroit, Michigan, 미국, 48236
- 모병
- Henry Ford Health Saint John Hospital
-
수석 연구원:
- Carrie Dul, MD
-
연락하다:
- 전화번호: 7347123671
- 이메일: MCRCwebsitecontactform@trinity-health.org
-
Flint, Michigan, 미국, 48503
- 모병
- Genesys Hurley Cancer Institute
-
수석 연구원:
- Paul Adams, MD
-
연락하다:
- 전화번호: 7347123671
- 이메일: MCRCwebsitecontactform@trinity-health.org
-
Grand Rapids, Michigan, 미국, 49503
- 모병
- Cancer Research Consortium of West Michigan
-
연락하다:
- Connie Szczepanek, RN
- 전화번호: 616-391-1230
- 이메일: crcwm-regulatory@crcwm.org
-
수석 연구원:
- Kathleen J. Yost, MD
-
Lansing, Michigan, 미국, 48912
- 모병
- University of Michigan Health - Sparrow Lansing
-
수석 연구원:
- Gordan Srkalovic, MD
-
연락하다:
- 전화번호: 7347123671
- 이메일: MCRCwebsitecontactform@trinity-health.org
-
Livonia, Michigan, 미국, 48154
- 모병
- Trinity Health Livonia Hospital
-
수석 연구원:
- Amit Mohindra, MD
-
연락하다:
- 전화번호: 7347127251
- 이메일: MCRCwebsitecontactform@trinity-health.org
-
Pontiac, Michigan, 미국, 48341
- 모병
- Trinity Health Oakland Hospital
-
수석 연구원:
- Julie Goodman, MD
-
연락하다:
- 전화번호: 7347123671
- 이메일: MCRCwebsitecontactform@trinity-health.org
-
Saginaw, Michigan, 미국, 48601
- 모병
- MyMichigan Medical Center Saginaw
-
수석 연구원:
- Nicholas Damico, MD
-
연락하다:
- 전화번호: 7347123671
- 이메일: MCRCwebsitecontactform@trinity-health.org
-
Traverse City, Michigan, 미국, 48341
- 모병
- Michigan Cancer Research Consortium
-
수석 연구원:
- Philip Stella, MD
-
연락하다:
- Beth LaVasseur, RN, MS
- 전화번호: 734-712-7251
- 이메일: Beth.LaVasseur@stjoeshealth.org
-
연락하다:
- 전화번호: 877-590-5995
-
Warren, Michigan, 미국, 48093
- 모병
- Henry Ford Health Warren Hospital
-
수석 연구원:
- Carrie Dul, MD
-
연락하다:
- 전화번호: 7347123671
- 이메일: MCRCwebsitecontactform@trinity-health.org
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68198
- 모병
- University of Nebraska Medical Center
-
수석 연구원:
- Alissa Marr, MD
-
연락하다:
- Micki Bethea, BS
- 전화번호: 402-559-8011
- 이메일: mbethea@unmc.edu
-
-
New Hampshire
-
Concord, New Hampshire, 미국, 03103
- 모병
- NH Oncology - Hematology, PA
-
연락하다:
- Ali Fleury
- 전화번호: 6033146888
- 이메일: A.Fleury@nhoh.com
-
수석 연구원:
- Michael Buff, MD
-
Manchester, New Hampshire, 미국, 03103
- 모병
- Solinsky Center for Cancer Care
-
연락하다:
- Ali Fleury, BA, CCRP
- 전화번호: 603-314-6888
- 이메일: A.Fleury@nhoh.com
-
수석 연구원:
- Michael Buff, MD
-
Portsmouth, New Hampshire, 미국, 03801
- 모병
- New England Cancer Specialist
-
수석 연구원:
- Christian Thomas, MD
-
연락하다:
- Patricia C Collins, BA, CCRC
- 전화번호: 2073033422
- 이메일: collip@newecs.org
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87110
- 모병
- Presbyterian Kaseman Hospital
-
수석 연구원:
- Bernard Tawfik, MD
-
연락하다:
- Monique Robertson, RN
- 전화번호: (505)- 559-6100
- 이메일: mrobertso2@phs.org
-
Albuquerque, New Mexico, 미국, 87102
- 모병
- Lovelace Medical Center - Saint Joseph Square
-
수석 연구원:
- Bernard Tawfik, MD
-
연락하다:
- Leslie Byatt
- 전화번호: (505) -925-0366
- 이메일: lpbyatt@salud.unm.edu
-
Albuquerque, New Mexico, 미국, 87131
- 모병
- The University of New Mexico Comprehensive Cancer Center
-
수석 연구원:
- Bernard Tawfik, MD
-
연락하다:
- Sheri Westgate, RN-BSN, OCN
- 전화번호: (505) -925-0383
- 이메일: swestgate@salud.unm.edu
-
Las Cruces, New Mexico, 미국, 88011
- 모병
- Memorial Medical Center
-
수석 연구원:
- Bernard Tawfik, MD
-
연락하다:
- Kim Hoffman, RN
- 전화번호: (575)- 556-6545
- 이메일: kim.hoffman@lpnt.net
-
Rio Rancho, New Mexico, 미국, 87124
- 모병
- Presbyterian Rust Medical Center
-
수석 연구원:
- Bernard Tawfik, MD
-
연락하다:
- Andrea Yost
- 전화번호: (505) -253-7878
- 이메일: ayost3@phs.org
-
-
New York
-
Lake Success, New York, 미국, 11042
- 모병
- Northwell Health Monter Cancer Center
-
연락하다:
- Mary Agnes Templeton
- 전화번호: 516-734-8979
- 이메일: mtempleton@northwell.edu
-
수석 연구원:
- Marina Frimer, MD
-
Mount Kisco, New York, 미국, 10549
- 모병
- Northern Westchester Hospital
-
수석 연구원:
- Marina Frimer, MD
-
연락하다:
- Jemima Jacob, MPH
- 전화번호: 914-666-1366
- 이메일: jjacob22@northwell.edu
-
New Hyde Park, New York, 미국, 11040
- 모병
- Cohen Children's Medical Center
-
연락하다:
- Shreya Seepersaud
- 전화번호: 718-470-7146
- 이메일: sseepersaud2@northwell.edu
-
수석 연구원:
- Marina Frimer, MD
-
New York, New York, 미국, 10065
- 모병
- Manhattan Eye, Ear, and Throat Hospital
-
수석 연구원:
- Marina Frimer, MD
-
연락하다:
- Leila Nasr
- 이메일: lnasr@northwell.edu
-
New York, New York, 미국, 10305
- 모병
- Staten Island University Hospital
-
수석 연구원:
- Marina Frimer, MD
-
연락하다:
- Sammi Ruan
- 전화번호: 718-226-1489
- 이메일: sruan2@northwell.edu
-
연락하다:
- Melissa McCarthy
- 전화번호: 718-226-1805
- 이메일: mccarthy22@northwell.edu
-
Rego Park, New York, 미국, 11374
- 모병
- Queens Cancer Center
-
수석 연구원:
- Marina Frimer, MD
-
연락하다:
- Harmandeep Kaur
- 전화번호: 718-412-0773
- 이메일: hkaur37@northwell.edu
-
Sleepy Hollow, New York, 미국, 10591
- 모병
- Phelps Hospital
-
수석 연구원:
- Marina Frimer, MD
-
연락하다:
- Barbara Turner, RN
- 전화번호: 914-269-1949
- 이메일: Bturner1@northwell.edu
-
연락하다:
- Shyrley Gomez
- 이메일: Sgomez21@northwell.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27599
- 모병
- Lineberger Comprehensive Cancer Center
-
수석 연구원:
- Shetal Patel, MD
-
연락하다:
- Emmie Cole
- 전화번호: 919-966-4432
- 이메일: emmie_cole@med.unc.edu
-
Charlotte, North Carolina, 미국, 28277
- 모병
- Atrium Health's Levine Cancer Institute
-
수석 연구원:
- Kathryn F. Mileham, MD, FACP
-
연락하다:
- Jenna Gregory, MS, RN
- 이메일: Jenna.Gregory@atriumhealth.org
-
-
North Dakota
-
Bismarck, North Dakota, 미국, 58501
- 모병
- Sanford Health- Bismarck
-
연락하다:
- Peter Kurniali, MD
- 전화번호: 701-323-5741
- 이메일: peter.kurniali@sanfordhealth.org
-
수석 연구원:
- Peter Kurniali, MD
-
Fargo, North Dakota, 미국, 58122
- 모병
- Sanford Health- Fargo
-
연락하다:
- Anu Gaba, MD
- 전화번호: 701-234-6161
- 이메일: anu.gaba@sanfordhealth.org
-
수석 연구원:
- Anu Gaba, MD
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45219
- 모병
- University of Cincinnati Medical Center
-
수석 연구원:
- Davendra Sohal, MD
-
연락하다:
- Kayla Webb, MSN, RN
- 전화번호: 513-584-0599
- 이메일: webb2ka@ucmail.uc.edu
-
Kettering, Ohio, 미국, 45429
- 모병
- Kettering Health
-
연락하다:
- Allison Dymacek, BSN, RN
- 전화번호: 937-395-8367
- 이메일: allison.dymacek@ketteringhealth.org
-
수석 연구원:
- Lex Leonhardt, DO
-
West Chester, Ohio, 미국, 45069
- 모병
- West Chester Hospital
-
수석 연구원:
- Trisha Wise-Draper, MD
-
연락하다:
- Kayla Webb, MSN, RN
- 전화번호: 513-584-0599
- 이메일: webb2ka@ucmail.uc.edu
-
-
Oregon
-
Portland, Oregon, 미국, 97213
- 모병
- Providence Health & Services
-
수석 연구원:
- Evthokia Hobbs, MD
-
연락하다:
- Isa Ngirailemesang
- 전화번호: 971-358-2056
- 이메일: Isa.Ngirailemesang@providence.org
-
-
Pennsylvania
-
Allentown, Pennsylvania, 미국, 18103
- 모병
- Lehigh Valley Hospital - Cedar Crest
-
연락하다:
- 전화번호: 734-712-3671
- 이메일: MCRCwebsitecontactform@trinity-health.org
-
수석 연구원:
- Maged Khalil, MD
-
Bethlehem, Pennsylvania, 미국, 18017
- 모병
- Lehigh Valley Hospital- Muhlenberg
-
수석 연구원:
- Maged Khalil, MD
-
연락하다:
- 전화번호: 7347127251
- 이메일: MCRCwebsitecontactform@trinity-health.org
-
East Stroudsburg, Pennsylvania, 미국, 18301
- 모병
- Pocono Medical Center
-
수석 연구원:
- Maged Khalil, MD
-
연락하다:
- 전화번호: 7347127251
- 이메일: MCRCwebsitecontactform@trinity-health.org
-
Hazleton, Pennsylvania, 미국, 18201
- 모병
- Lehigh Valley Hospital-Hazleton
-
수석 연구원:
- Maged Khalil, MD
-
연락하다:
- 전화번호: 7347127251
- 이메일: MCRCwebsitecontactform@trinity-health.org
-
Philadelphia, Pennsylvania, 미국, 19111
- 모병
- Fox Chase Cancer Center
-
수석 연구원:
- Margaret von Mehren, MD
-
연락하다:
- Fathima S Sheriff
- 전화번호: 215-728-4094
- 이메일: fathima.sheriff@fccc.edu
-
-
South Carolina
-
Bluffton, South Carolina, 미국, 29910
- 모병
- SC Cancer Specialists at St. Joseph's/Candler Bluffton
-
수석 연구원:
- Mark Taylor, MD
-
연락하다:
- Stephanie Smith, RN, MSN, OCN
- 전화번호: 19128195723
- 이메일: smiths1@sjchs.org
-
Bluffton, South Carolina, 미국, 29910
- 모병
- St. Joseph's/Candler Smith
-
수석 연구원:
- Mark Taylor, MD
-
연락하다:
- Stephanie Smith, RN, MSN, OCN
- 전화번호: 19128195723
- 이메일: smiths1@sjchs.org
-
Bluffton, South Carolina, 미국, 29910
- 모병
- Summit Cancer Care at St. Josph's/Candler Bluffton
-
수석 연구원:
- Mark Taylor, MD
-
연락하다:
- Stephanie Smith, RN, MSN, OCN
- 전화번호: 19128195723
- 이메일: smiths1@sjchs.org
-
Hilton Head Island, South Carolina, 미국, 29926
- 모병
- South Carolina Cancer Specialists
-
수석 연구원:
- Mark Taylor, MD
-
연락하다:
- Stephanie Smith, RN, MSN, OCN
- 전화번호: 19128195723
- 이메일: smiths1@sjchs.org
-
-
South Dakota
-
Sioux Falls, South Dakota, 미국, 57104
- 모병
- Sanford Cancer Center Oncology Clinic and Pharmacy
-
수석 연구원:
- Steven Powell, MD
-
연락하다:
- Steven Powell, MD
- 전화번호: 605-328-8000
- 이메일: steven.powell@sanfordhealth.org
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- 모병
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute
-
연락하다:
- Ethan Trull
- 전화번호: 615-329-7274
- 이메일: Ethan.Trull@SarahCannon.com
-
수석 연구원:
- Meredith McKean, MD, MPH
-
-
Texas
-
Houston, Texas, 미국, 77030
- 모병
- The University of Texas MD Anderson Cancer Center
-
수석 연구원:
- Funda Meric-Bernstam, MD
-
연락하다:
- Kshipra Sharma, MPH, MS
- 전화번호: 713-745-8431
- 이메일: Ksharma2@MDAnderson.org
-
-
Utah
-
Cedar City, Utah, 미국, 84720
- 모병
- Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center
-
수석 연구원:
- Ramya Thota, MD
-
연락하다:
- Jake Kolu
- 전화번호: 435-705-1632
- 이메일: Jake.Kolu@imail.org
-
수석 연구원:
- Derrick Haslem, MD
-
Salt Lake City, Utah, 미국, 84107
- 모병
- Intermountain Healthcare
-
연락하다:
- Tracy Taylor
- 전화번호: 801-507-3953
- 이메일: tracy.taylor@imail.org
-
수석 연구원:
- Ramya Thota, M.D.
-
수석 연구원:
- Derrick Haslem, M.D.
-
St. George, Utah, 미국, 84770
- 모병
- Dixie Regional Medical Center-River Road Campus
-
수석 연구원:
- Ramya Thota, MD
-
연락하다:
- Jake Kolu
- 전화번호: 435-705-1632
- 이메일: Jake.Kolu@imail.org
-
수석 연구원:
- Derrick Haslem, MD
-
-
Virginia
-
Fairfax, Virginia, 미국, 22042
- 모병
- Inova Schar Cancer Institute
-
수석 연구원:
- Timothy Cannon, MD
-
연락하다:
- Roxana Comfort, CRC
- 전화번호: 571-472-0628
- 이메일: roxana.comfort@inova.org
-
-
Washington
-
Bonney Lake, Washington, 미국, 98391
- 모병
- Northwest Medical Specialties
-
연락하다:
- Jennifer Spokely
- 전화번호: 253-999-3701
- 이메일: research@southsoundcare.org
-
수석 연구원:
- Frank Senecal, MD
-
Federal Way, Washington, 미국, 98003
- 모병
- Northwest Medical Specialties
-
연락하다:
- Jennifer Spokely
- 전화번호: 253-999-3701
- 이메일: research@southsoundcare.org
-
수석 연구원:
- Frank Senecal, MD
-
Gig Harbor, Washington, 미국, 98332
- 모병
- Northwest Medical Specialties
-
연락하다:
- Jennifer Spokely
- 전화번호: 253-999-3701
- 이메일: research@southsoundcare.org
-
수석 연구원:
- Frank Senecal, MD
-
Olympia, Washington, 미국, 98502
- 모병
- Northwest Medical Specialties
-
연락하다:
- Jennifer Spokely
- 전화번호: 253-999-3701
- 이메일: research@southsoundcare.org
-
수석 연구원:
- Frank Senecal, MD
-
Puyallup, Washington, 미국, 98373
- 모병
- Northwest Medical Specialties
-
수석 연구원:
- Frank Senecal, MD
-
연락하다:
- Jennifer Spokely
- 전화번호: 253-999-3701
- 이메일: reserch@southsoundcare.org
-
Seattle, Washington, 미국, 98104
- 모병
- Swedish Cancer Institute
-
수석 연구원:
- Philip Gold, MD
-
연락하다:
- Sidney Ching
- 전화번호: 206-386-3142
- 이메일: sidney.ching@swedish.org
-
Tacoma, Washington, 미국, 98405
- 모병
- Northwest Medical Specialties
-
수석 연구원:
- Frank Senecal, MD
-
연락하다:
- Jennifer Spokely
- 전화번호: 253-999-3701
- 이메일: reserch@southsoundcare.org
-
-
Wisconsin
-
Burlington, Wisconsin, 미국, 53105
- 모병
- Aurora Cancer Care - Burlington
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle Toutloff, RN, CCRP
- 전화번호: 9204567880
- 이메일: Michelle.Martin2@aah.org
-
Germantown, Wisconsin, 미국, 53022
- 모병
- Aurora Health Care - Germantown Health Center
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle Toutloff, RN, CCRP
- 전화번호: 9204567880
- 이메일: Michelle.Martin2@aah.org
-
Grafton, Wisconsin, 미국, 53024
- 모병
- Aurora Cancer Care - Grafton
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle Toutloff, RN, CCRP
- 전화번호: 9204567880
- 이메일: Michelle.Martin2@aah.org
-
Green Bay, Wisconsin, 미국, 54311
- 모병
- Aurora BayCare Medical Center
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle Toutloff, RN, CCRP
- 전화번호: 9204567880
- 이메일: Michelle.Martin2@aah.org
-
Kenosha, Wisconsin, 미국, 53142
- 모병
- Aurora Cancer Care - Kenosha South
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle Toutloff, RN, CCRP
- 전화번호: 9204567880
- 이메일: Michelle.Martin2@aah.org
-
Marinette, Wisconsin, 미국, 54143
- 모병
- Aurora Bay Area Medical Center
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle Toutloff, RN, CCRP
- 전화번호: 9204567880
- 이메일: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, 미국, 53215
- 모병
- Aurora St. Luke's Medical Center
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle M Toutloff, RN, CCRP
- 전화번호: 9204567880
- 이메일: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, 미국, 53209
- 모병
- Aurora Cancer Care Milwaukee
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle M Toutloff, RN, CCRP
- 전화번호: 9204567880
- 이메일: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, 미국, 53223
- 모병
- Aurora Sinai Medical Center
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle Toutloff, RN, CCRP
- 전화번호: 9204567880
- 이메일: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, 미국, 53227
- 모병
- Aurora West Allis Medical Center
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle Toutloff, RN, CCRP
- 전화번호: 9204567880
- 이메일: Michelle.Martin2@aah.org
-
Oshkosh, Wisconsin, 미국, 54904
- 모병
- Vince Lombardi Cancer Clinic - Oshkosh
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle Toutloff, RN, CCRP
- 전화번호: 9204567880
- 이메일: Michelle.Martin2@aah.org
-
Racine, Wisconsin, 미국, 53406
- 모병
- Aurora Cancer Care - Racine
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle Toutloff, RN, CCRP
- 전화번호: 9204567880
- 이메일: Michelle.Martin2@aah.org
-
Sheboygan, Wisconsin, 미국, 53081
- 모병
- Vince Lombardi Cancer Center
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle Toutloff, RN, CCRP
- 전화번호: 9204567880
- 이메일: Michelle.Martin2@aah.org
-
Summit, Wisconsin, 미국, 53066
- 모병
- Aurora Medical Center in Summit
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle Toutloff, RN, CCRP
- 전화번호: 9204567880
- 이메일: Michelle.Martin2@aah.org
-
Two Rivers, Wisconsin, 미국, 54241
- 모병
- Vince Lombardi Cancer Clinic - Two Rivers
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle Toutloff, RN, CCRP
- 전화번호: 9204567880
- 이메일: Michelle.Martin2@aah.org
-
Wauwatosa, Wisconsin, 미국, 53226
- 모병
- Aurora Cancer Care - Milwaukee West
-
수석 연구원:
- Antony Ruggeri, MD
-
연락하다:
- Michelle Toutloff, RN, CCRP
- 전화번호: 920-456-7880
- 이메일: Michelle.Martin2@aah.org
-
-
-
-
Puerto Rico
-
Cayey, Puerto Rico, 푸에르토 리코, 00737
- 모병
- PanOncology Trials
-
연락하다:
- Natalia Ortiz
- 전화번호: 787-407-3333
- 이메일: natalia.ortiz@panoncologytrials.com
-
수석 연구원:
- Maria Cruz Correa, MD
-
Dorado, Puerto Rico, 푸에르토 리코, 00646
- 모병
- PanOncology Trials
-
연락하다:
- Natalia Ortiz
- 전화번호: 787-407-3333
- 이메일: natalia.ortiz@panoncologytrials.com
-
수석 연구원:
- Maria Cruz Correa, MD
-
Manati, Puerto Rico, 푸에르토 리코, 00674
- 모병
- PanOncology Trials
-
연락하다:
- Natalia Ortiz
- 전화번호: 787-407-3333
- 이메일: natalia.ortiz@panoncologytrials.com
-
수석 연구원:
- Maria Crus Correa, MD
-
Mayagüez, Puerto Rico, 푸에르토 리코, 00680
- 모병
- PanOncology Trials
-
연락하다:
- Natalia Ortiz
- 전화번호: 787-407-3333
- 이메일: natalia.ortiz@panoncologytrials.com
-
수석 연구원:
- Maria Cruz Correa, MD
-
Ponce, Puerto Rico, 푸에르토 리코, 00730
- 모병
- PanOncology Trials
-
연락하다:
- Natalia Ortiz
- 전화번호: 787-407-3333
- 이메일: natalia.ortiz@panoncologytrials.com
-
수석 연구원:
- Maria Cruz Correa, MD
-
San Juan, Puerto Rico, 푸에르토 리코, 00909
- 모병
- PanOncology Trials
-
연락하다:
- Natalia Ortiz
- 전화번호: 787-407-3333
- 이메일: natalia.ortiz@panoncologytrials.com
-
수석 연구원:
- Maria Cruz Correa, MD
-
San Juan, Puerto Rico, 푸에르토 리코, 00935
- 모병
- PanOncology Trials
-
연락하다:
- Natalia Ortiz
- 전화번호: 787-407-3333
- 이메일: natalia.ortiz@panoncologytrials.com
-
수석 연구원:
- Maria Cruz Correa, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)
-
Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated (except under the circumstance in which the TAPUR arm is designed to provide additional evidence to support an existing FDA indication).
-
Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
-
Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:
- Absolute neutrophil count ≥ 1500 µl
- Hemoglobin ≥ 9.0 g/dl
- Platelets ≥ 75,000/µl
- Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
- Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
- Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
-
Patients must have disease that can be objectively measured by physical, laboratory or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma).
-
Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
-
Ability to understand and the willingness to sign a written informed consent/assent document.
-
Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
-
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
-
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study treatment, or completely abstain from sexual intercourse.
Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.
Exclusion Criteria:
- Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
- Patients with primary brain tumors or new, untreated or progressive leptomeningeal metastases are excluded
- Patients with previously treated brain metastases or previously treated leptomeningeal disease are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 1 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
- Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.
Note: there are additional exclusion criteria that may apply
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
다른: Group 5 (CSF1R,PDGFR,VEGFR)
Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations |
drug
다른 이름들:
|
|
다른: Group 8 (ERBB2)
Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
drug
다른 이름들:
|
|
다른: Group 9 (BRAF V600E/D/K/R)
Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations |
drug
다른 이름들:
|
|
다른: Group 14 (BRCA1/2; ATM)
Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions |
drug
다른 이름들:
|
|
다른: Group 16 (MSI-H, high mutational load and others)
Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations |
drug
다른 이름들:
|
|
다른: Group 17 (CDKN2A, CDK4, CDK6)
Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation |
drug
다른 이름들:
|
|
다른: Group 19 (BRCA1/2, PALB2)
Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations |
drug
다른 이름들:
|
|
다른: Group 21 (BRCA1/2, PALB2, ATM, and others)
Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval |
drug
다른 이름들:
|
|
다른: Group 24 (ERBB2)
Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
drug
다른 이름들:
|
|
다른: Group 25
Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation |
drug
다른 이름들:
|
|
다른: Group 26 (BRAF V600 E mutation )
Participants receive Dabrafenib plus Trametinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600 E mutation . |
Drug
다른 이름들:
|
|
다른: Group 27 (ERBB2 amplification, ERBB2 (HER2) IHC2+ or IHC3+ overexpression)
Participants receive Fam-trastuzumab deruxtecan-nxki (ENHERTU®) - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification, For NSCLC Only-ERBB2 (HER2) IHC2+ or IHC3+ overexpression without ERBB2 amplification) |
Drug
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
기간: Assessed at 16 weeks of treatment
|
Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used. |
Assessed at 16 weeks of treatment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall survival (OS)
기간: Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
|
OS will be estimated using the Kaplan-Meier method |
Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 Aug 1;39(22):2443-2451. doi: 10.1200/JCO.20.02923. Epub 2021 Apr 12.
- Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):733-741. doi: 10.1007/s11523-020-00753-7.
- Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):743-750. doi: 10.1007/s11523-020-00752-8.
- Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 Oct;6:e2200306. doi: 10.1200/PO.22.00306.
- Mangat PK, Kirkwood MK, Hinshaw DC, Garrett-Mayer E, Schilsky RL. Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study. NPJ Precis Oncol. 2025 Jul 3;9(1):222. doi: 10.1038/s41698-025-00962-1.
- Worden FP, Pisick E, Rothe M, Mangat PK, Garrett-Mayer E, Khalil MF, Carrizosa DR, Bauman JR, Leidner RS, Duvivier HL, Fu S, Park MS, Yost KJ, Calfa CJ, Marr AS, Balmanoukian AS, Behl D, Cannon TL, Nabell L, Powell SF, Thota R, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct;8:e2400477. doi: 10.1200/PO-24-00477. Epub 2024 Oct 16.
- Schuetze S, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Calfa CJ, Farrington LC, Livingston MB, Wentzel K, Behl D, Kier Y, Marr AS, von Mehren M, Press JZ, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jul;8:e2400219. doi: 10.1200/PO.24.00219.
- Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Brouse G, Chan J, Mehmi I, Khalil M, Duvivier HL, Gaba A, Leuva H, Thota R, Yost KJ, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jun;8:e2400026. doi: 10.1200/PO.24.00026.
- Cannon TL, Rothe M, Mangat PK, Garrett-Mayer E, Chiu VK, Hwang J, Vijayvergia N, Alese OB, Dib EG, Duvivier HL, Klute KA, Sahai V, Ahn ER, Bedano P, Behl D, Sinclair S, Thota R, Urba WJ, Yang ES, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2024 Sep 20;42(27):3228-3237. doi: 10.1200/JCO.23.02078. Epub 2024 May 15.
- Perez JK, Kleber J, Rothe M, Mangat P, Garrett-Mayer E, Schilsky RL. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar;8:e2300615. doi: 10.1200/PO.23.00615.
- Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb;8:e2300513. doi: 10.1200/PO.23.00513.
- Meric-Bernstam F, Rothe M, Mangat PK, Garrett-Mayer E, Gutierrez R, Ahn ER, Cannon TL, Powell S, Krauss JC, Reynolds CM, von Mehren M, Behl D, Calfa CJ, Duvivier HL, Kaplan HG, Livingston MB, Sharma MR, Urba WJ, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Sep;7:e2300385. doi: 10.1200/PO.23.00385.
- Rohatgi N, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Pisick E, Alese OB, Reynolds CM, Thota R, Vaccaro GM, von Mehren M, Arend RC, Chiu VK, Duvivier HL, Gold PJ, Hack K, Marr AS, Winer A, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep;7:e2300279. doi: 10.1200/PO.23.00279.
- Duvivier HL, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Al Baghdadi T, Alva AS, Dublis SA, Cannon TL, Calfa CJ, Li R, Behl D, Chiu VK, Gold PJ, Marr AS, Mileham KF, Powell SF, Rodon J, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2023 Nov 20;41(33):5140-5150. doi: 10.1200/JCO.23.00702. Epub 2023 Aug 10.
- Mangat PK, Garrett-Mayer E, Perez JK, Schilsky RL. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. Clin Trials. 2023 Dec;20(6):699-707. doi: 10.1177/17407745231182013. Epub 2023 Jul 25.
- Ganti AK, Rothe M, Mangat PK, Garrett-Mayer E, Dib EG, Duvivier HL, Ahn ER, Behl D, Borghaei H, Balmanoukian AS, Gaba A, Li R, Osei-Boateng K, Thota R, Grantham GN, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Jun;7:e2300041. doi: 10.1200/PO.23.00041.
- Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Ali-Ahmad HM, Chan J, Maitland ML, Patel SR, Reese Z, Balmanoukian AS, Drescher CW, Li R, Tsimberidou AM, Leath CA 3rd, O'Lone R, Grantham GN, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Apr;7:e2200609. doi: 10.1200/PO.22.00609.
- Yang ES, Halabi S, Rothe M, Garrett-Mayer E, Mangat PK, Pisick E, Dib E, Burgess EF, Zakem M, Rohatgi N, Bilen MA, O'Lone R, Grantham GN, Schilsky RL. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Feb;7:e2200505. doi: 10.1200/PO.22.00505.
- Carrizosa DR, Rothe M, Mangat PK, Garrett-Mayer E, Behl D, Adesunloye B, Pisick E, Beekman KW, Dotan E, Akce M, Alese OB, Sahai V, Klute KA, Aragon-Ching JB, Cooper KA, Thota R, Meric-Bernstam F, Hosein PJ, Maestas EC, Moyers JT, Powell S, Zhao S, Hobbs E, Rueter J, Sohal DPS, Taylor MA, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Jan;10:e2500716. doi: 10.1200/PO-25-00716. Epub 2026 Jan 15.
- Al Baghdadi T, Rothe M, Mangat PK, Garrett-Mayer E, Crysler OV, Mileham KF, Farrington LC, Adesunloye B, Dublis SA, Astsaturov I, Calfa CJ, Bleeker J, Khalil M, Thota R, Cannon TL, Alese OB, Gold PJ, Hafez N, Baron AD, Meric-Bernstam F, Hobbs E, Marr AS, Rueter J, Tawfik B, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2025 Oct;9:e2500649. doi: 10.1200/PO-25-00649. Epub 2025 Oct 16.
- Cobain EF, Rothe M, Garrett-Mayer E, Cannon TL, Chan JK, Mileham KF, Adesunloye B, Calfa CJ, Alese OB, Butler KY, Dib EG, Pisick E, Bell M, Klute KA, Mehmi I, Meric-Bernstam F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Apr;10(4):e2501205. doi: 10.1200/PO-25-01205. Epub 2026 Apr 30.
- Pisick E, Rothe M, Garrett-Mayer E, Srkalovic G, Chan JK, Calfa CJ, Leath CA 3rd, Marr AS, Gold PJ, Crane EK, Moyers JT, Yost Butler K, Gaba A, Thota R, Harnden KK, Alese OB, Jain A, Rueter J, Gill S, George TJ, Frimer M, Kayali F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Apr;10(4):e2500985. doi: 10.1200/PO-25-00985. Epub 2026 Apr 22.
- Veljovich DS, Rothe M, Garrett-Mayer E, Ali-Ahmad HM, Naumann RW, Siedel J, Chan JK, Gregory A, Pisick E, Adesunloye B, Arend RC, Bell M, Frimer M, Tawfik B, Thota R, Tsimberidou AM, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Jul;10(7):e2600456. doi: 10.1200/PO-26-00456. Epub 2026 Jul 15.
- Diamond-Rossi SA, Rothe M, Garrett-Mayer E, Pisick E, Bleeker J, Ganti AK, Meric-Bernstam F, Moyers JT, Nair SG, Kadakia KC, Rohatgi N, Sahai V, Vijayvergia N, Gold PJ, Sharma MR, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study. JCO Precis Oncol. 2026 Oct;10(10):e2600703. doi: 10.1200/PO-26-00703. Epub 2026 Oct 16.
- Srkalovic G, Rothe M, Garrett-Mayer E, Mileham KF, Adesunloye B, Pisick E, Leath CA 3rd, Colocci N, Chen MD, Meric-Bernstam F, Marr AS, Alese OB, Powell S, Rueter J, Benyounes A, Pontious C, Lewis MA, Thomas GW, Kier Y, Calfa CJ, von Mehren M, Acoba JD, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Oct;10(10):e2600454. doi: 10.1200/PO-26-00454. Epub 2026 Oct 7.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 혈관 질환
- 심혈관 질환
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 혈액 질환
- 림프계 질환
- 림프 증식 장애
- 면역증식성 장애
- 림프종
- 신생물, 형질세포
- 지혈 장애
- 파라단백혈증
- 혈액 단백질 장애
- 출혈성 장애
- 헴 및 림프병
- 신생물
- 다발성 골수종
- 림프종, 비호지킨
- 아미노산, 펩티드 및 단백질
- 단백질
- 황 화합물
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- Azoles
- 아미드
- 인돌
- 항체, 모노클로 날, 인간화
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 피롤
- 설폰 아미드
- 설폰
- 트라스투주맙
- 수니티닙
- 니볼루맙
- 이필리무맙
- 베무라페닙
- Abemaciclib
- 페르 투 주맙
- dabrafenib
- 트라 메티 닙
- 아테 졸리 주맙
- 올라 파리브
- Talazoparib
- 코비 메티 닙
- 투 카티 닙
- Futibatinib
기타 연구 ID 번호
- Pro00014171
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .